http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Choi, Changhoon,Lee, Chansu,Shin, Sung-Won,Kim, Shin-Yeong,Hong, Sung Noh,Park, Hee Chul MDPI 2019 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol.20 No.8
<P>When radiotherapy is applied to the abdomen or pelvis, normal tissue toxicity in the gastrointestinal (GI) tract is considered a major dose-limiting factor. Proton beam therapy has a specific advantage in terms of reduced doses to normal tissues. This study investigated the fundamental differences between proton- and X-ray-induced intestinal injuries in mouse models. C57BL/6J mice were irradiated with 6-MV X-rays or 230-MeV protons and were sacrificed after 84 h. The number of surviving crypts per circumference of the jejunum was identified using Hematoxylin and Eosin staining. Diverse intestinal stem cell (ISC) populations and apoptotic cells were analyzed using immunohistochemistry (IHC) and a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) assay, respectively. The crypt microcolony assay revealed a radiation-dose-dependent decrease in the number of regenerative crypts in the mouse jejunum; proton irradiation was more effective than X-ray irradiation with a relative biological effectiveness of 1.14. The jejunum is the most sensitive to radiations, followed by the ileum and the colon. Both types of radiation therapy decreased the number of radiosensitive, active cycling ISC populations. However, a higher number of radioresistant, reserve ISC populations and Paneth cells were eradicated by proton irradiation than X-ray irradiation, as shown in the IHC analyses. The TUNEL assay revealed that proton irradiation was more effective in enhancing apoptotic cell death than X-ray irradiation. This study conducted a detailed analysis on the effects of proton irradiation versus X-ray irradiation on intestinal crypt regeneration in mouse models. Our findings revealed that proton irradiation has a direct effect on ISC populations, which may result in an increase in the risk of GI toxicity during proton beam therapy.</P>
Yonghoon Choi,Changhoon Choi,Joonwon Bae,Jongnam Park,Kyusoon Shin 한국공업화학회 2023 Journal of Industrial and Engineering Chemistry Vol.123 No.-
Group III–Ⅴ quantum dots (QDs) are preferred over Group Ⅱ–Ⅵmaterials because of their relatively mildtoxicity. In this study, a facile synthetic method to obtain gallium phosphide (GaP) QDs with color conversionperformance is reported. Colloidal GaP QDs were produced via a hot-injection method using anoptimized combination of precursors. The products showed controllable emissions from 400 to 520 nm,depending on the band gap. High photoluminescence (PL) quantum yields of 35–40% with a full width athalf maximum (FWHM) of 75 nm were achieved in the green emission region. In addition, the greenemissionGaP QDs were applied as a color-conversion material for optical devices with UV and blueLED chips. An average color conversion efficiency of 15% was achieved. This study demonstrates the possibilityof using GaP QDs as a competitive color-conversion material.
( Won-mook Choi ),( Jonggi Choi ),( Danbi Lee ),( Ju Hyun Shim ),( Kang Mo Kim ),( Young-suk Lim ),( Han Chu Lee ),( Changhoon Yoo ),( Sook Ryun Park ),( Min-hee Ryu ),( Baek-yeol Ryoo ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Nivolumab showed durable response and safety in patients with hepatocellular carcinoma (HCC) in the previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child-Pugh class B, is lacking. We aimed to investigate the efficacy and safety of nivolumab in a real- world cohort of patients with advanced HCC. Methods: This study retrospectively evaluated 203 patients with HCC who were treated with nivolumab between July 2017 to February 2019. Radiologic evaluation was based on mRECIST. Survival outcomes were estimated by Kaplan-Meier method and Cox proportional hazard model. Logistic regression model was used to identify the predictive factors of treatment response. Results: Of 203 patients, 132 patients were within Child-Pugh class A and 71 patients were within Child-Pugh class B. Objective response rate was lower in patients with Child-Pugh class B than A (2.8% vs. 15.9%; P=0.010 by unweighted analysis and P=0.034 by weighted analysis) and Child-Pugh class was an independent predictor for objective response (Odds ratio, 0.21; 95% confidence interval; 0.05-0.93; P=0.040). Median overall survival was shorter in Child-Pugh B patients (11.3 vs. 42.9 weeks; P<0.001 by both unweighted and weighted analyses). However, other efficacy outcomes including disease control rate, time to progression, and progression-free survival were comparable between Child-Pugh A and B patients by unadjusted, adjusted, matched, and weighted analyses. There was no significant difference in terms of safety between Child-Pugh A and B patients. Conclusions: Given the limited treatment options for advanced HCC in Child-Pugh B patients, nivolumab may be a viable option despite lower response in these patients. Further studies are needed in this patient population.